Printer Friendly

US FDA receives New Drug Application for Heron Therapeutics' CINVANTI.

M2 PHARMA-January 16, 2017-US FDA receives New Drug Application for Heron Therapeutics' CINVANTI

(C)2017 M2 COMMUNICATIONS

The US Food and Drug Administration (FDA) has received a New Drug Application from United States-based Heron Therapeutics for its CINVANTI (HTX-019), a polysorbate 80-free, intravenous formulation of aprepitant for the prevention of Chemotherapy-Induced Nausea and Vomiting (CINV), it was reported on Friday.

The New Drug Application filing includes data demonstrating the bioequivalence of CINVANTI to EMEND IV (fosaprepitant), supporting its efficacy for the prevention of both acute and delayed CINV with both moderately emetogenic chemotherapy and highly emetogenic chemotherapy.

Results also indicated that the product was better tolerated than EMEND IV, with significantly fewer adverse events reported with CINVANTI.

The product is a proprietary intravenous formulation of aprepitant, a NK1 receptor antagonist intended for the prevention of CINV. NK1 receptor antagonists are typically used in combination with 5-HT3 receptor antagonists.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jan 16, 2017
Words:159
Previous Article:OncoImmune receives USD15m in Series A round of fundraising.
Next Article:Eli Lilly reports extension of US FDA review period for once-daily oral investigational baricitinib NDA for rheumatoid arthritis.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters